Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership

Core Insights - Femasys Inc. has partnered with Kebomed to commercialize FemBloc Permanent Birth Control in France and the Benelux region, significantly enhancing market access for this innovative product [1][2] - The collaboration is a key part of Femasys' European growth strategy following the recent CE mark approval for FemBloc, which is the only non-surgical permanent birth control option available [1][4] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of products [3] - The company's lead product innovations include FemBloc and FemaSeed, with clinical data showing FemaSeed is over twice as effective as traditional IUI [3] Product Details - FemBloc is a non-surgical solution for permanent birth control that uses a patented delivery system to occlude fallopian tubes, offering a safer and more cost-effective alternative to surgical sterilization [2][4] - The product has received full regulatory approval in Europe, the UK, and New Zealand, with ongoing efforts for U.S. FDA approval through the FINALE pivotal trial [4] Strategic Partnership - Kebomed, a leading independent distributor of medical devices in Europe, will leverage its established infrastructure and expertise in women's health to drive the adoption of FemBloc [2][6] - The partnership aims to unlock significant growth potential in key European markets, particularly in France, which represents the largest market opportunity for FemBloc [2][6]